Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er septembre 2021
September 23, 2021 01:00 ET
|
INNATE PHARMA
Marseille, 23 sept. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma...
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021
September 23, 2021 01:00 ET
|
INNATE PHARMA
Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés...
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021
September 23, 2021 01:00 ET
|
INNATE PHARMA
MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...
Présentation de Données Issues de l'Essai COAST Comprenant Monalizumab au Congrès de l'ESMO 2021
September 17, 2021 07:45 ET
|
INNATE PHARMA
Marseille, France, 17 sept. 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd'hui qu’AstraZeneca (LSE/STO/Nasdaq : AZN)...
Monalizumab Data From COAST Trial Presented at ESMO Congress 2021
September 17, 2021 07:45 ET
|
INNATE PHARMA
Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN)...
Monalizumab Data from COAST Trial Presented at ESMO Congress 2021
September 17, 2021 07:45 ET
|
INNATE PHARMA
MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN)...
Innate Pharma présente ses résultats financiers et l'avancée de son portefeuille au premier semestre 2021
September 15, 2021 01:00 ET
|
INNATE PHARMA
Marseille, 15 sept. 2021 (GLOBE NEWSWIRE) -- Les premières données cliniques de TELLOMAK ont établi un taux de réponse global encourageant de 35% avec lacutamab, ainsi qu’une amélioration au niveau...
Innate Pharma reports first half 2021 financial results and business update
September 15, 2021 01:00 ET
|
INNATE PHARMA
Marseille, Sept. 15, 2021 (GLOBE NEWSWIRE) -- First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with...
Innate Pharma Reports First Half 2021 Financial Results and Business Update
September 15, 2021 01:00 ET
|
INNATE PHARMA
First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2New...
Rapport Financier Semestriel 30 juin 2021
September 15, 2021 01:00 ET
|
INNATE PHARMA
Marseille, 15 sept. 2021 (GLOBE NEWSWIRE) -- RAPPORT FINANCIER SEMESTRIEL30 JUIN 2021 INNATE PHARMA S.A.Société anonyme à Directoire et Conseil de surveillanceau capital social de 3 952 095,85...